ADMA Biologics (NASDAQ:ADMA) Stock Rating Upgraded by Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

A number of other equities analysts have also recently issued reports on ADMA. Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Canaccord Genuity Group lowered their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Raymond James Financial began coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, ADMA Biologics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Stock Up 0.7%

ADMA opened at $9.58 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 13.69 and a beta of 0.78. ADMA Biologics has a one year low of $7.21 and a one year high of $20.46. The business’s fifty day moving average is $9.13 and its two-hundred day moving average is $10.31.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. During the same quarter last year, the business posted $0.14 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. Analysts anticipate that ADMA Biologics will post 0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of ADMA Biologics during the second quarter valued at approximately $321,037,000. State Street Corp grew its stake in ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after acquiring an additional 35,614 shares during the period. Sachem Head Capital Management LP grew its stake in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP raised its holdings in ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors raised its holdings in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.